Botulinum Toxin for the Treatment of Movement Disorders

Overview

Journal Curr Neurol Neurosci Rep

Specialty Neurology

Date 2012 Jun 5

PMID 22661378

Citations 16

Authors

Mary Ann Thenganatt

Stanley Fahn

Affiliations

Soon will be listed here.

Abstract

After botulinum toxin was initially used to treat strabismus in the 1970s, others started using it to treat movement disorders including blepharospasm, hemifacial spasm, cervical dystonia, spasmodic dysphonia, and oromandibular dystonia. It was discovered that botulinum toxin can be an effective treatment for focal movement disorders with limited side effects. Over the past three decades, various formulations of botulinum toxin have been developed and the therapeutic use of these toxins has expanded in movement disorders and beyond. We review the history and mechanism of action of botulinum toxin, as well as describe different formulations available and their potential therapeutic uses in movement disorders.

Citing Articles

Botulinum toxin treatment for hemifacial spasm: harmonising neurological and aesthetic outcomes.

Maytharakcheep S, Bhidayasiri R J Neural Transm (Vienna). 2024; 132(1):23-38.

PMID: 39174752 DOI: 10.1007/s00702-024-02821-y.

Bruxism and Botulinum Injection: Challenges and Insights.

Malcangi G, Patano A, Pezzolla C, Riccaldo L, Mancini A, Di Pede C J Clin Med. 2023; 12(14).

PMID: 37510701 PMC: 10380379. DOI: 10.3390/jcm12144586.

Efficacy and Safety of Botulinum Toxin A and Pulsed Radiofrequency on Postherpetic Neuralgia: A Randomized Clinical Trial.

Chen L, Zhang Y, Chen Y, Wang T, Sun K, Tang H Contrast Media Mol Imaging. 2022; 2022:1579937.

PMID: 35685657 PMC: 9170518. DOI: 10.1155/2022/1579937.

European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment.

Roessner V, Eichele H, Stern J, Skov L, Rizzo R, Mol Debes N Eur Child Adolesc Psychiatry. 2021; 31(3):425-441.

PMID: 34757514 PMC: 8940878. DOI: 10.1007/s00787-021-01899-z.

Harnessing the Membrane Translocation Properties of AB Toxins for Therapeutic Applications.

Piot N, van der Goot F, Sergeeva O Toxins (Basel). 2021; 13(1).

PMID: 33418946 PMC: 7825107. DOI: 10.3390/toxins13010036.

References

Yoshimura D, Aminoff M, Tami T, Scott A . Treatment of hemifacial spasm with botulinum toxin. Muscle Nerve. 1992; 15(9):1045-9. DOI: 10.1002/mus.880150909. View

Dressler D, Benecke R . Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol. 2002; 49(1):34-8. DOI: 10.1159/000067023. View

Odergren T, Hjaltason H, Kaakkola S, Solders G, Hanko J, Fehling C . A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1998; 64(1):6-12. PMC: 2169916. DOI: 10.1136/jnnp.64.1.6. View

Brin M, Fahn S, Moskowitz C, Friedman A, Shale H, Greene P . Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord. 1987; 2(4):237-54. DOI: 10.1002/mds.870020402. View

Warrick P, Dromey C, Irish J, Durkin L, Pakiam A, Lang A . Botulinum toxin for essential tremor of the voice with multiple anatomical sites of tremor: a crossover design study of unilateral versus bilateral injection. Laryngoscope. 2000; 110(8):1366-74. DOI: 10.1097/00005537-200008000-00028. View

Rosales R, Dressler D . On muscle spindles, dystonia and botulinum toxin. Eur J Neurol. 2010; 17 Suppl 1:71-80. DOI: 10.1111/j.1468-1331.2010.03056.x. View

Simpson D, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M . Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008; 70(19):1699-706. PMC: 5565261. DOI: 10.1212/01.wnl.0000311389.26145.95. View

Adler C, Bansberg S, Krein-Jones K, Hentz J . Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia. Mov Disord. 2004; 19(9):1075-9. DOI: 10.1002/mds.20098. View

Dressler D, Dirnberger G . Botulinum toxin antibody testing: comparison between the immunoprecipitation assay and the mouse diaphragm assay. Eur Neurol. 2001; 45(4):257-60. DOI: 10.1159/000052139. View

10.

Dressler D, Munchau A, Bhatia K, Quinn N, Bigalke H . Antibody-induced botulinum toxin therapy failure: can it be overcome by increased botulinum toxin doses?. Eur Neurol. 2002; 47(2):118-21. DOI: 10.1159/000047963. View

11.

Schneider S, Edwards M, Cordivari C, Macleod W, Bhatia K . Botulinum toxin A may be efficacious as treatment for jaw tremor in Parkinson's disease. Mov Disord. 2006; 21(10):1722-4. DOI: 10.1002/mds.21019. View

12.

Kanovsky P, Slawek J, Denes Z, Platz T, Sassin I, Comes G . Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. Clin Neuropharmacol. 2009; 32(5):259-65. DOI: 10.1097/WNF.0b013e3181b13308. View

13.

Scott A, Kennedy R, Stubbs H . Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol. 1985; 103(3):347-50. DOI: 10.1001/archopht.1985.01050030043017. View

14.

Tintner R, Gross R, Winzer U, Smalky K, Jankovic J . Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial. Neurology. 2005; 65(5):765-7. DOI: 10.1212/01.wnl.0000174433.76707.8c. View

15.

BOROFF D, Chen G . On the question of permeability of the blood-brain barrier to botulinum toxin. Int Arch Allergy Appl Immunol. 1975; 48(4):495-504. DOI: 10.1159/000231337. View

16.

Wissel J, Masuhr F, Schelosky L, Ebersbach G, Poewe W . Quantitative assessment of botulinum toxin treatment in 43 patients with head tremor. Mov Disord. 1997; 12(5):722-6. DOI: 10.1002/mds.870120516. View

17.

Blitzer A, Brin M, Fahn S, LOVELACE R . Localized injections of botulinum toxin for the treatment of focal laryngeal dystonia (spastic dysphonia). Laryngoscope. 1988; 98(2):193-7. DOI: 10.1288/00005537-198802000-00015. View

18.

Greene P, Kang U, Fahn S, Brin M, Moskowitz C, Flaster E . Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology. 1990; 40(8):1213-8. DOI: 10.1212/wnl.40.8.1213. View

19.

Pellizzari R, Rossetto O, Schiavo G, Montecucco C . Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Philos Trans R Soc Lond B Biol Sci. 1999; 354(1381):259-68. PMC: 1692495. DOI: 10.1098/rstb.1999.0377. View

20.

Molloy F, Shill H, Kaelin-Lang A, Karp B . Accuracy of muscle localization without EMG: implications for treatment of limb dystonia. Neurology. 2002; 58(5):805-7. DOI: 10.1212/wnl.58.5.805. View